



## Recombinant Botulinum Toxin A/B Vaccine

### rBV A/B

#### Description

The Recombinant Botulinum Toxin A/B Vaccine is intended to protect against aerosolized exposure to botulinum toxins. The Recombinant Botulinum Toxin A/B Vaccine (rBV A/B) is comprised of non-toxic but immunogenic fragments of the botulinum toxin heavy chains of serotypes A and B. Initial development for this product was pioneered at the US Army Medical Research Institute of Infectious Diseases. Currently, Dynport Vaccine Company is the MCS-JVAP prime system contractor and regulatory sponsor for this advanced development effort. The Milestone C / Low Rate Initial Production decision is in 2018, with Food and Drug Administration approval planned for 2022. The vaccine is intended for use in an active vaccination program and will be administered intramuscularly as a three dose primary series prior to deployment of Warfighters into possible threat areas.



#### Mission

Provide protection against weaponized botulinum toxin serotypes A (subtype A1) and B (subtype B1).

#### Capabilities

- Biological Prophylaxis

#### Users

US Navy, US Marine Corps, US Army, US Air Force

#### Status

Engineering and Manufacturing Development - Anticipated Fielding: FY 2024 Q2

This Fact Sheet was cleared for public release on 6/15/2015.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@mail.mil,  
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919